Molecular Formula | C19H21ClFNO3 |
Molar Mass | 365.83 |
Melting Point | 129-131°C |
Boling Point | 451.7°C at 760 mmHg |
Flash Point | 227°C |
Vapor Presure | 2.39E-08mmHg at 25°C |
Appearance | neat |
Storage Condition | 2-8°C |
Physical and Chemical Properties | melting point 129-131°C |
Use | Antidepressants |
UN IDs | 3249 |
HS Code | 29339900 |
Hazard Class | 6.1(b) |
Packing Group | III |
This product is (1)-(3S,4R)-4-(4-fluorophenyl)-3-[(3, 4-methylenedioxy) phenoxy] methyl] piperidine hydrochloride hemihydrate. C19H20FN03 • HCl shall not be less than 98.5% calculated as anhydrous and solvent-free.
take this product, precision weighing, add methanol to dissolve and quantitatively dilute the solution containing lOmg per lml, and determine according to law (General 0621), the specific rotation is from one to 88 ° to one to 91 °.
take 0.10g of this product, Add 10ml of water, heat to dissolve, cool, and determine according to law (General 0631),pH value should be 5.5~6.5.
take this product, precision weigh, add methanol to dissolve and quantitatively dilute to make a solution containing about 1 mg per 1ml, as a test solution; Take 1ml for precision, in a 100ml measuring flask, dilute to the scale with methanol, shake well, and use as a control solution, methanol was added to dissolve and diluted to make each containing 0. A mixed solution of 1 mg is used as a system-applicable solution. a-acid glycoprotein bonded silica gel was used as a filler (0512 × 4.0mm, 5um) as determined by high performance liquid chromatography (General 11.4), 1000ml of water was added to dissolve, and the pH value was adjusted to 6.5 with phosphoric acid. Acetonitrile (94:6) was used as mobile phase; The detection wavelength was 295nm, and the column temperature was 30°C. Take the system applicable solution 10u1 and inject it into human Liquid Chromatograph. The resolution of paroxetine peak and trans-paroxetine peak should be greater than 2.2. Take 10ul of control solution and 10ul of test solution, respectively inject human liquid chromatograph, record chromatogram. If there is a trans-paroxetine peak in the chromatogram of the test solution, the peak area shall not be greater than 0.1 times (0.1%) of the main peak area of the control solution.
This product was taken, dissolved and diluted with a solvent [tetrahydrofuran-water (1:9 )] to prepare a solution containing about 1 mg per 1 ml as a test solution. An appropriate amount was taken in a precise amount and quantitatively diluted with a solvent to prepare a solution containing about 1 ug per 1 ml as a control solution. Take the control of paroxetine hydrochloride, desfluraxetine (impurity I) and N-methylparoxetine (impurity II), dissolve with solvent and dilute to prepare 10% mixed solution per 1 ml, as a system suitability solution. According to the high performance liquid chromatography (General 0512) test, with octyl silane bonded silica gel as filler; With trifluoroacetic acid-tetrahydrofuran-water (5:100:900) as mobile phase A, trifluoroacetic acid-tetrahydrofuran-acetonitrile (5:100:900) was used as mobile Phase B, and gradient elution was carried out according to the following table. The detection wavelength was 295mn. Take 20ul of the applicable solution of the system, inject the human liquid chromatograph, record the chromatogram, the order of peaks are impurity I, impurity II and paroxetine, paroxetine peak, the degree of separation between the impurity I peak and the impurity D peak should be greater than 2.5. 20 u1 of the control solution and the test solution were respectively injected into the liquid chromatograph, and the chromatograms were recorded. If there is a chromatographic peak consistent with the retention time of impurity I in the chromatogram of the test solution, the peak area shall not be greater than the main peak area of the control solution (0.1%), other single impurity peak area shall not be greater than the main peak area of the control solution (0.1%), and the sum of each impurity peak area shall not be greater than 5 times (0.5%) of the main peak area of the control solution. The chromatogram of the test solution is 0.5 times smaller than the main peak area of the control solution.
take this product about 2.0g, precision weighing, put it in 20ml measuring flask, Precision Add internal standard solution (take the right amount of N-propanol, with dimethyl sulfoxide to make a solution containing about 5mg per 1 ml) 2ml, diluted with dimethyl sulfoxide to the scale, shake, as a test solution. Accurately weigh the appropriate amount of methanol, ethanol, acetone, Tetrahydrofuran, pyridine and toluene, and use dimethyl methylene to make 3mg, 5mg, 5mg and 0.72mg for each lml, 0.2mg and 0.89mg of the solution were used as the reference stock solution; 5ml of each of the reference stock solution and the internal standard solution were accurately weighed, placed in a 50ml measuring flask, diluted to the scale with dimethyl sulfoxide, and shaken, as a control solution. Take 10ml of each of the reference solution and the test solution, respectively place them in the headspace bottle and seal them. According to the test for determination of residual solvents (General rule 0861 second method), the capillary column with 6% cyanopropylphenyl-94% dimethylpolysiloxane (or similar polarity) as stationary liquid is used as the column; The initial temperature is 50 ℃, hold for 10 minutes, raise the temperature to 80°C at a rate of 6°C per minute, hold for 5 minutes, then raise the temperature to 150°C at a rate of 40°C per minute, hold for 5 minutes; The equilibrium temperature of the headspace bottle is 90°C, the equilibration time was 30 minutes. The reference solution is injected into the headspace, and the chromatogram is recorded. The number of theoretical plates is not less than 10000 based on the N-propanol peak, and the separation degree of each component peak shall meet the requirements. Then take the reference solution and the test solution into the headspace respectively, record the chromatogram, according to the internal standard method to calculate the peak area, methanol, ethyl fermentation, acetone, Tetrahydrofuran, the residues of pyridine and toluene shall be in accordance with the regulations.
take this product, according to the determination method of moisture (General 0832 first method 1), the water content is divided into 2.0% ~ 3.0%.
take l.Og of this product and check it according to law (General rule 0841). The residue left shall not exceed 0.1%.
The residue left under the item of burning residues shall be inspected according to law (General Principles 0821, Law II) and shall not contain more than 10 parts per million of heavy metals.
antidepressants.
sealed storage.
This product contains paroxetine hydrochloride in Paroxetine (C19H20FN03), should be 93.0% ~ 107.0% of the label amount.
This product is a film-coated tablet, white or off-white after removal of the coating.
In the chromatogram recorded under the content determination item, the retention time of the main peak of the test solution should be consistent with the retention time of the main peak of the control solution.
Take 10 tablets of this product, precision weighing, fine grinding, precision weighing take an appropriate amount (about equivalent to paroxetine 10 mg), dissolved and diluted with mobile phase to make about 0 per 1 ml. 1 mg of the solution was shaken, filtered, and the filtrate was taken. As a test solution, it was obtained by measuring according to the method under the item of paroxetine hydrochloride content measurement.
antidepressants.
20mg (based on C19H20FN03)
light shielding, sealed storage.